<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673567</url>
  </required_header>
  <id_info>
    <org_study_id>TV48125-PK-10078</org_study_id>
    <nct_id>NCT02673567</nct_id>
  </id_info>
  <brief_title>To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Administration of TEV-48125 (Single Ascending Doses and Single Doses up to 900 mg) in Japanese and Caucasian Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, double-blind, placebo-controlled study to assess the
      pharmacokinetics, safety, and tolerability of subcutaneous administration of TEV-48125
      (single ascending doses and single doses up to 900 mg) in Japanese and Caucasian healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2016</start_date>
  <completion_date type="Actual">February 10, 2017</completion_date>
  <primary_completion_date type="Actual">December 16, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma drug concentration (tmax)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to the time of the last measurable plasma drug concentration (AUC0-t)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to 672 hours (4 weeks) postdose (AUC0-672)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage extrapolated AUC (%AUCext)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent serum terminal elimination rate constant (λz)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance (CL/F)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution during the terminal phase (Vz/F)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent serum terminal elimination half-life (t½)</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>33 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability- Percentage of participants who fail to complete the study</measure>
    <time_frame>33 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who fail to complete the study due to adverse events</measure>
    <time_frame>33 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>TEV-48125 - 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Regimen 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEV-48125 - 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Regimen 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEV-48125 - 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Regimen 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-48125 - 1</intervention_name>
    <description>Subcutaneous administration Dose Regimen 1</description>
    <arm_group_label>TEV-48125 - 1</arm_group_label>
    <other_name>monoclonal antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-48125 - 2</intervention_name>
    <description>Subcutaneous administration Dose Regimen 2</description>
    <arm_group_label>TEV-48125 - 2</arm_group_label>
    <other_name>monoclonal antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-48125 - 3</intervention_name>
    <description>Subcutaneous administration Dose Regimen 3</description>
    <arm_group_label>TEV-48125 - 3</arm_group_label>
    <other_name>monoclonal antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is a man or woman, 18 to 55 years of age, inclusive

          -  The subject has a body mass index (BMI) ranging from 17.5 to 28.0 kg/m2, inclusive

          -  The subjects must be in a good health at screening and check-in

        Additional inclusion criteria for Japanese subjects:

          -  Subject must be a non-naturalized Japanese citizen and hold a Japanese passport

          -  Subject must have/had 2 Japanese parents and 4 Japanese grandparents who are all non
             naturalized Japanese citizens

          -  Subject has been living outside of Japan for no more than 10 years

        Additional inclusion criteria for Caucasian subjects:

          -  The subject has/had 2 Caucasian parents and 4 Caucasian grandparents. Caucasian
             includes White and Hispanic ethnicities.

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  The subject is a woman who is pregnant or lactating

          -  The subject is suffering from, or has a clinically significant history of, 1 or more
             of the following: cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             endocrine, neurological, immunological, hematologic or psychiatric disorder(s)

          -  The subject has a known allergy or sensitivity to injected proteins, including
             monoclonal antibodies, or any other component of the formulation. In addition,
             presence of history of allergies requiring acute or chronic treatment

          -  Precipitation in another clinical study of a new investigational drug within 30 days
             (90 days for biologics) before dosing

               -  Additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 13529</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

